Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01076348 · ClinicalTrials.gov registry record

Model 4965 Post-Approval Study

A clinical trial of Heart Failure and Bradycardia, sponsored by Medtronic.

Completed
Registry status
73
Enrollment target
20
Study locations

NCT01076348 is a study of Heart Failure and Bradycardia that has completed, run by Medtronic. The registered enrollment target is 73 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01076348, a study of Heart Failure and Bradycardia, has completed, sponsored by Medtronic.

COMPLETED
Registry status
73 participants
Enrollment target
20
Study locations

Study Summary

Safety and effectiveness will be summarized for the model 4965 lead. This study was conducted within Medtronic's System Longevity Study (SLS).

Study Locations (20)

California

  • - Bakersfield
  • - Chula Vista
  • - Downey
  • - East Palo Alto
  • - Los Angeles
  • - Salinas
  • - Torrance
  • - Van Nuys

Florida

  • - Clearwater
  • - Jacksonville
  • - Melbourne
  • - Ocala

Arizona

  • - Phoenix
  • - Scottsdale

Colorado

  • - Colorado Springs
  • - Denver

Alabama

  • - Birmingham

Alaska

  • - Anchorage

Arkansas

  • - Little Rock

District of Columbia

  • - Washington D.C.

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 1996-09
Est. Completion 2011-04

Sponsor

Medtronic

30 total trials

What the Registry Record Tells You About NCT01076348

The ClinicalTrials.gov registry entry for NCT01076348 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower). The listed sponsor is Medtronic, which has 30 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 0 interventions.

NCT01076348 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT01076348 about?

NCT01076348 is a clinical study titled "Model 4965 Post-Approval Study". Safety and effectiveness will be summarized for the model 4965 lead. This study was conducted within Medtronic's System Longevity Study (SLS).

What is the current status of trial NCT01076348?

This trial is currently completed. The enrollment target is 73 participants. The study started on 1996-09. Estimated completion is 2011-04.

What conditions does trial NCT01076348 study?

This clinical trial studies the following conditions: Heart Failure, Bradycardia, Arrhythmia, Pacing.

Who is sponsoring clinical trial NCT01076348?

This trial is sponsored by Medtronic, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01076348 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.